Skip to main content

Advertisement

SpringerLink
Log in

The Role of CDK4/6 Inhibitors in Breast Cancer

  • Breast Cancer (EA Comen, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Oral inhibitors of CDK4/6 have been shown to increase response rates and prolong disease control when combined with endocrine therapy in hormone-responsive (HR+) HER2-negative advanced breast cancer. Palbociclib, ribociclib and abemaciclib are all approved in combination with non-steroidal aromatase inhibitors in first-line therapy for post-menopausal women, with a 40–45% improvement in progression-free survival seen with the addition of any of these CDK4/6 inhibitors. Additional approved indications, including first- and second-line combination therapy for pre-menopausal women, combination with fulvestrant and use as monotherapy, vary with each agent and are reviewed fully in the subsequent texts. These agents also differ in their toxicity profiles and monitoring requirements, and prescribers should be aware of the individual requirements for each agent. Current clinical trials are investigating the expanded use of these agents in other breast cancer subtypes, such as HER2-positive and triple-negative breast cancer, as well as in the adjuvant and neoadjuvant treatments of early breast cancer. Resistance to CDK4/6 inhibition can occur through multiple mechanisms. Rational combinations with other therapies, such as PI3K inhibitors, HER2-directed therapies and immunotherapy, are being explored.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Hanrahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.

    Article  Google Scholar 

  2. Dukelow T, Kishan D, Khasraw M, Murphy CG. CDK4/6 inhibitors in breast cancer. Anticancer Drugs. 2015;26(8):797–806.

    Article  CAS  Google Scholar 

  3. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70.

    Article  Google Scholar 

  4. Jessen BA, Lee L, Koudriakova T, Haines M, Lundgren K, Price S, et al. Peripheral white blood cell toxicity induced by broad spectrum cyclin-dependent kinase inhibitors. J Appl Toxicol. 2007;27(2):133–42.

    Article  CAS  Google Scholar 

  5. Murphy CG, Dickler MN. The role of CDK4/6 inhibition in breast cancer. Oncologist. 2015;20(5):483–90.

    Article  CAS  Google Scholar 

  6. Finn RS, Dering J, Conklin D, et al. PD 0332991, a selective cyclin D kinase 4/6inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11(5):R77.

    Article  Google Scholar 

  7. Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25–35.

    Article  CAS  Google Scholar 

  8. •• Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, et al. Palbociclib and Letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925–36 This phase 3 study provided the basis for the approval of palbociclib with an aromatase inhibitor as initial endocrine therapy of advanced HR+, HER2-negative breast cancer in post-menopausal women.

    Article  CAS  Google Scholar 

  9. •• Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425–39 This phase 3 study provided the basis for the approval of palbociclib in combination with fulvestrant in pre- and post-menopausal women with disease progression following endocrine therapy.

    Article  CAS  Google Scholar 

  10. Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, et al. Overall survival with Palbociclib and Fulvestrant in advanced breast cancer. N Engl J Med. 2018;379(20):1926–36.

    Article  CAS  Google Scholar 

  11. Tanguy ML, Cabel L, Berger F, Pierga JY, Savignoni A, Bidard FC. Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer. NPJ Breast Cancer. 2018;4:14.

    Article  Google Scholar 

  12. Diéras V, Rugo HS, Schnell P, Gelmon K, Cristofanilli M, Loi S, et al. Long-term pooled safety analysis of Palbociclib in combination with endocrine therapy for HR+/HER2- advanced breast cancer. J Natl Cancer Inst. 2018. https://doi.org/10.1093/jnci/djy109.

    Article  Google Scholar 

  13. Kim S, Loo A, Chopra R, Caponigro G, Huang A, Vora S, et al. Abstract PR02: LEE011: an orally bioavailable, selective small molecule inhibitor of CDK4/6-reactivating Rb in cancer. Mol Cancer Ther. 2013;12(11 Suppl):PR02.

    Google Scholar 

  14. Infante JR, Cassier PA, Gerecitano JF, Witteveen PO, Chugh R, Ribrag V, et al. A phase I study of the cyclin-dependent kinase 4/6 inhibitor Ribociclib (LEE011) in patients with advanced solid tumors and lymphomas. Clin Cancer Res. 2016;22(23):5696–705.

    Article  CAS  Google Scholar 

  15. •• Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738–48 This phase 3 study provided the basis for the approval of ribociclib in combination with an aromatase inhibitor as initial endocrine therapy for the treatment of HR+, HER2-negative advanced breast cancer in postmenopausal women.

    Article  CAS  Google Scholar 

  16. Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018;29(7):1541–7.

    CAS  PubMed  Google Scholar 

  17. • Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19(7):904–15 This study provided the basis for the approval of ribociclib with an aromatase inhibitor and ovarian function suppression for premenopausal women with HR+, HER2-negative advanced breast cancer.

    Article  CAS  Google Scholar 

  18. •• Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, et al. Phase III randomized study of Ribociclib and Fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36(24):2465–72 This phase 3 study provided the basis for the approval of ribociclib in combination with fulvestrant for the treatment of postmenopausal women with HR+, HER2-negative advanced breast cancer, as initial endocrine based therapy or following disease progression on endocrine therapy.

    Article  CAS  Google Scholar 

  19. US Food and Drug Administration. Prescribing information for ribociclib. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209092s001lbl.pdf. Accessed online 15 January 2019.

  20. US Food and Drug Administration. FDA approves new treatment for certain advanced or metastatic breast cancers. Press release, September 28 2017. Available at www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm578071.htm. Accessed online 15 January 2019.

  21. US Food and Drug Administration. Prescribing information for abemaciclib. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208855s000lbl.pdf. Accessed online 15 January 2019.

  22. •• Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875–84 This phase 3 study provided the basis for the approval of abemaciclib in combination with fulvestrant in the treatment of post-menopausal women with HR+, HER2-negative advanced breast cancer with disease progression following endocrine therapy.

    Article  CAS  Google Scholar 

  23. • Dickler MN, Tolaney SM, Rugo HS, Cortés J, Diéras V, Patt D, et al. MONARCH 1, a phase II study of Abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer. Clin Cancer Res. 2017;23(17):5218–24 This phase 2 study provided the basis for the approval of abemaciclib as monotherapy in patients with HR+, HER2-negative advanced breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.

    Article  CAS  Google Scholar 

  24. •• Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, et al. MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35(32):3638–46 This phase 3 study provided the basis for the approval of abemaciclib with an aromatase inhibitor as initial endocrine therapy of advanced HR+, HER2-negative breast cancer in post-menopausal women.

    Article  CAS  Google Scholar 

  25. Finn RS, Liu Y, Martin M, Rugo HS, Dieras V, Im SA, et al. Abstract P2-09-10: comprehensive gene expression biomarker analysis of CDK 4/6 and endocrine pathways from the PALOMA-2 study. Cancer Res. 2018;78(4 Supplement):P2-09-10.

    Google Scholar 

  26. Raspé E, Coulonval K, Pita JM, Paternot S, Rothé F, Twyffels L, et al. CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib. EMBO Mol Med. 2017;9(8):1052–66.

    Article  Google Scholar 

  27. Malorni L, Piazza S, Ciani Y, Guarducci C, Bonechi M, Biagioni C, et al. A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer. Oncotarget. 2016;7(42):68012–22.

    Article  Google Scholar 

  28. O’Leary B, Cutts RJ, Liu Y, Hrebien S, Huang X, Fenwick K, et al. The genetic landscape and clonal evolution of breast cancer resistance to Palbociclib plus Fulvestrant in the PALOMA-3 trial. Cancer Discov. 2018;8(11):1390–403.

    Article  Google Scholar 

  29. Taylor-Harding B, Aspuria PJ, Agadjanian H, Cheon DJ, Mizuno T, Greenberg D, et al. Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS. Oncotarget. 2015;6(2):696–714.

    Article  Google Scholar 

  30. Herrera-Abreu MT, Palafox M, Asghar U, Rivas MA, Cutts RJ, Garcia-Murillas I, et al. Early adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor-positive breast cancer. Cancer Res. 2016;76(8):2301–13.

    Article  CAS  Google Scholar 

  31. Jansen VM, Bhola NE, Bauer JA, Formisano L, Lee KM, Hutchinson KE, et al. Kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4/6 inhibition in ER-positive breast cancer. Cancer Res. 2017;77(9):2488–99.

    Article  CAS  Google Scholar 

  32. O’Leary B, Hrebien S, Morden JP, Beaney M, Fribbens C, Huang X, et al. Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer. Nat Commun. 2018;9(1):896.

    Article  Google Scholar 

  33. Yang C, Li Z, Bhatt T, Dickler M, Giri D, Scaltriti M, et al. Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence. Oncogene. 2017;36(16):2255–64.

    Article  CAS  Google Scholar 

  34. Yang ZJ, Chee CE, Huang S, Sinicrope FA. The role of autophagy in cancer: therapeutic implications. Mol Cancer Ther. 2011;10(9):1533–41.

    Article  CAS  Google Scholar 

  35. Vijayaraghavan S, Karakas C, Doostan I, Chen X, Bui T, Yi M, et al. CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers. Nat Commun. 2017;8:15916.

    Article  CAS  Google Scholar 

  36. Parrish KE, Pokorny J, Mittapalli RK, Bakken K, Sarkaria JN, Elmquist WF. Efflux transporters at the blood-brain barrier limit delivery and efficacy of cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor model. J Pharmacol Exp Ther. 2015;355(2):264–71.

    Article  CAS  Google Scholar 

  37. Patel Y. PDTB-12. CNS penetration of the CDK4/6 inhibitor ribociclib (LEE011) in non-tumor bearing mice and mice bearing orthotopic pediatric brain tumors. Neuro Oncol. 2016;18:vi152.

    Article  Google Scholar 

  38. Raub TJ, Wishart GN, Kulanthaivel P, Staton BA, Ajamie RT, Sawada GA, et al. Brain exposure of two selective dual CDK4 and CDK6 inhibitors and the antitumor activity of CDK4 and CDK6 inhibition in combination with temozolomide in an intracranial glioblastoma xenograft. Drug Metab Dispos. 2015;43(9):1360–71.

    Article  CAS  Google Scholar 

  39. Yin L, Li H, Liu W, Yao Z, Cheng Z, Zhang H, et al. A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy. Eur J Med Chem. 2018;144:1–28.

    Article  CAS  Google Scholar 

  40. Bardia A, Yardley DA, Hurvitz S, Wright G, Moroose R, Ma C, et al. Abstract PD5-11: Ribociclib in combination with everolimus and exemestane in men and postmenopausal women with HR+/HER2− advanced breast cancer following progression on a CDK4/6 inhibitor: efficacy and updated safety and pharmacokinetic results from phase 1 of the TRINITI-1 study. Cancer Res. 2018;78(4 Suppl):PD5–11.

    Google Scholar 

  41. Beeram M, Tolaney SM, Beck JT, Dickler MN, Conlin AK, Dees C, et al. Abstract LBA-18: a phase 1 study of Abemaciclib, an inhibitor of CDK4 and CDK6 in combination with endocrine and HER2 targeted therapies for patients with metastatic breast cancer. Ann Oncol. 2016;27((suppl_6)):LBA–18.

    Google Scholar 

  42. • Goel S, DeCristo MJ, Watt AC, BrinJones H, Sceneay J, Li BB, et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature. 2017;548(7668):471–5 This landmark study provides a preclinical rationale for the combination of CDK4/6 inhibitors with immune checkpoint blockade in breast cancer.

    Article  CAS  Google Scholar 

  43. Deng J, Wang ES, Jenkins RW, Li S, Dries R, Yates K, et al. CDK4/6 inhibition augments antitumor immunity by enhancing T cell activation. Cancer Discov. 2018;8(2):216–33.

    Article  CAS  Google Scholar 

  44. Pembrolizumab, Letrozole, and Palbociclib in treating postmenopausal patients with newly diagnosed metastatic stage IV estrogen receptor positive breast cancer. Available at https://clinicaltrials.gov/ct2/show/NCT02778685. Accessed online 15 January 2019.

  45. Ameratunga M, Kipps E, Okines AFC, Lopez JS. To cycle or fight—CDK4/6 inhibitors at the crossroads of anticancer immunity. Clin Cancer Res. 2019;25(1):21–8.

    Article  Google Scholar 

  46. Barton VN, D’Amato NC, Gordon MA, Lind HT, Spoelstra NS, Babbs BL, et al. Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo. Mol Cancer Ther. 2015;14(3):769–78.

    Article  CAS  Google Scholar 

  47. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750–67.

    Article  CAS  Google Scholar 

  48. Asghar US, Barr AR, Cutts R, Beaney M, Babina I, Sampath D, et al. Single-cell dynamics determines response to CDK4/6 inhibition in triple-negative breast cancer. Clin Cancer Res. 2017;23(18):5561–72.

    Article  CAS  Google Scholar 

  49. Liu CY, Lau KY, Hsu CC, Chen JL, Lee CH, Huang TT, et al. Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells. PLoS One. 2017;12(12):e0189007.

    Article  Google Scholar 

  50. Ribociclib and Bicalutamide in AR+ TNBC. Available at https://clinicaltrials.gov/ct2/show/NCT03090165. Accessed online 15 January 2019.

  51. Teo ZL, Versaci S, Dushyanthen S, Caramia F, Savas P, Mintoff CP, et al. Combined CDK4/6 and PI3Kα inhibition is synergistic and immunogenic in triple-negative breast cancer. Cancer Res. 2017;77(22):6340–52.

    Article  CAS  Google Scholar 

  52. Witkiewicz AK, Cox D, Knudsen ES. CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models. Genes Cancer. 2014;5(7–8):261–72.

    CAS  PubMed  PubMed Central  Google Scholar 

  53. Goel S, Wang Q, Watt AC, Tolaney SM, Dillon DA, Li W, et al. Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4/6 inhibitors. Cancer Cell. 2016;29(3):255–69.

    Article  CAS  Google Scholar 

  54. Gianni L, Bisagni G, Colleoni M, Del Mastro L, Zamagni C, Mansutti M, et al. Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study. Lancet Oncol. 2018;19(2):249–56.

    Article  CAS  Google Scholar 

  55. Ma CX, Gao F, Luo J, Northfelt DW, Goetz M, Forero A, et al. NeoPalAna: neoadjuvant Palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and Anastrozole for clinical stage 2 or 3 estrogen receptor-positive breast cancer. Clin Cancer Res. 2017;23(15):4055–65.

    Article  CAS  Google Scholar 

  56. Curigliano G, Gómez Pardo P, Meric-Bernstam F, Conte P, Lolkema MP, Beck JT, et al. Ribociclib plus letrozole in early breast cancer: a presurgical, window-of-opportunity study. Breast. 2016;28:191–8.

    Article  CAS  Google Scholar 

  57. Chow LWC, Morita S, Chow CYC, Ng WK, Toi M. Neoadjuvant palbociclib on ER+ breast cancer (N007): clinical response and EndoPredict’s value. Endocr Relat Cancer. 2018;25(2):123–30.

    Article  CAS  Google Scholar 

  58. Johnston S, Puhalla S, Wheatley D, Ring A, Barry P, Holcombe C, et al. Randomized phase II study evaluating Palbociclib in addition to Letrozole as neoadjuvant therapy in estrogen receptor-positive early breast cancer: PALLET trial. J Clin Oncol. 2018;JCO1801624. https://doi.org/10.1200/JCO.18.01624.

    Article  Google Scholar 

  59. Cottu P, D’Hondt V, Dureau S, Lerebours F, Desmoulins I, Heudel PE, et al. Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer. Ann Oncol. 2018;29(12):2334–40.

    Article  CAS  Google Scholar 

  60. A study of Palbociclib in addition to standard endocrine treatment in hormone receptor positive Her2 normal patients with residual disease after neoadjuvant chemotherapy and surgery (PENELOPE-B). Available at https://clinicaltrials.gov/ct2/show/NCT01864746. Accessed online 15 January 2019.

  61. PALbociclib CoLlaborative adjuvant study: a randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+)/human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (PALLAS). Available at https://clinicaltrials.gov/ct2/show/NCT02513394. Accessed online 15 January 2019.

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Bon Secours Hospital, College Road, Cork, Ireland

    Conleth G. Murphy MB, BCh, BAO

  2. University College Cork, Cork, Ireland

    Conleth G. Murphy MB, BCh, BAO

Authors
  1. Conleth G. Murphy MB, BCh, BAO
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Conleth G. Murphy MB, BCh, BAO.

Ethics declarations

Conflict of Interest

Conleth G. Murphy declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the author.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Breast Cancer

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Murphy, C.G. The Role of CDK4/6 Inhibitors in Breast Cancer. Curr. Treat. Options in Oncol. 20, 52 (2019). https://doi.org/10.1007/s11864-019-0651-4

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11864-019-0651-4

Keywords

Search

Navigation